S100A2 and neoplasm: Although S100A2 is a ligand of the receptor for advanced glycation end products (RAGEs) [14], which participate in melanoma progression by promoting tumor growth, anti-RAGE antibody treatment reduces tumor growth in vitro [78], S100A2 might have other action points in melanoma to exert antitumor action against melanoma.